StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.41−0.03 (-2.08%)

Close on Nov 18, 2026Market cap $117.61MP/E –Yield –

Pyxis Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Pyxis Oncology's operating income for the twelve months ending Jun 30, 2026 was -$92.11M. For fiscal 2025 it was -$84.42M. The highest annual figure on record is -$12.89M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$84.42M–
FY2024Dec 31, 2024-$89.46M–
FY2023Dec 31, 2023-$82.20M–
FY2022Dec 31, 2022-$123.48M–
FY2021Dec 31, 2021-$69.72M–
FY2020Dec 31, 2020-$12.89M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$25.99M–
Q1 FY2026Mar 31, 2026-$24.36M–
Q4 FY2025Dec 31, 2025-$18.30M–
Q3 FY2025Sep 30, 2025-$23.46M–
Q2 FY2025Jun 30, 2025-$19.75M–
Q1 FY2025Mar 31, 2025-$22.91M–
Q4 FY2024Dec 31, 2024-$40.07M–
Q3 FY2024Sep 30, 2024-$23.75M–
Q2 FY2024Jun 30, 2024-$20.03M–
Q1 FY2024Mar 31, 2024-$5.61M–
Q4 FY2023Dec 31, 2023-$17.77M–
Q3 FY2023Sep 30, 2023-$25.35M–
Q2 FY2023Jun 30, 2023-$18.12M–
Q1 FY2023Mar 31, 2023-$20.95M–
Q4 FY2022Dec 31, 2022-$37.97M–
Q3 FY2022Sep 30, 2022-$28.39M–
Q2 FY2022Jun 30, 2022-$25.73M–
Q1 FY2022Mar 31, 2022-$31.39M–
Q4 FY2021Dec 31, 2021-$16.43M–
Q3 FY2021Sep 30, 2021-$11.62M–
Q2 FY2021Jun 30, 2021-$5.94M–
Q1 FY2021Mar 31, 2021-$35.73M–
Q4 FY2020Dec 31, 2020-$4.58M–
Q3 FY2020Sep 30, 2020-$3.19M–

More Pyxis Oncology figures

See a number that looks wrong?